What is he best known for?
The fields of study he is best known for:
- Immune system
- Antibody
- Gene
Scott Koenig spends much of his time researching Virology, Antibody, Immunology, Virus and Monoclonal antibody.
His Virology research integrates issues from Cell culture, Antigen, Immune system and Microbiology.
As a member of one scientific family, Scott Koenig mostly works in the field of Antibody, focusing on Effector and, on occasion, Molecular biology, Specific antibody, In vitro and Immunotherapy.
His Immunology research incorporates themes from Cytotoxic T cell, Receptor and Acquired immunodeficiency syndrome.
His specific area of interest is Virus, where Scott Koenig studies Retrovirus.
His Monoclonal antibody research is multidisciplinary, incorporating elements of Cross-presentation, Fc receptor, Epitope, Interleukin 12 and In vivo.
His most cited work include:
- Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. (2538 citations)
- Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. (1461 citations)
- A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. (681 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Virology, Antibody, Immunology, Antigen and Molecular biology.
Scott Koenig has researched Virology in several fields, including Epitope, Acquired immunodeficiency syndrome and Microbiology.
His Antibody study combines topics in areas such as Cancer, Receptor, Immune system and Effector.
His Immunology research focuses on Cytotoxic T cell and how it connects with CD8, T lymphocyte, Human leukocyte antigen and Cellular immunity.
In his study, Cancer cell and Antibody-drug conjugate is strongly linked to Cancer research, which falls under the umbrella field of Antigen.
He has included themes like Amino acid, In vitro, Antibody-dependent cell-mediated cytotoxicity and B cell in his Molecular biology study.
He most often published in these fields:
- Virology (38.25%)
- Antibody (38.25%)
- Immunology (33.33%)
What were the highlights of his more recent work (between 2010-2021)?
- Antibody (38.25%)
- Immunology (33.33%)
- Monoclonal antibody (15.85%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Antibody, Immunology, Monoclonal antibody, Cancer research and Epitope.
His Antibody research focuses on subjects like Effector, which are linked to T-cell receptor.
His research in Immunology is mostly focused on Virus.
The Virus study which covers Cytotoxic T cell that intersects with Immunotherapy and Peripheral blood mononuclear cell.
His Cancer research study integrates concerns from other disciplines, such as Cancer cell, Cancer, Antibody-drug conjugate and Antigen.
His Virology research includes themes of Antigen binding, CD3 and Cell killing.
Between 2010 and 2021, his most popular works were:
- Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. (327 citations)
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma (243 citations)
- Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity (157 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Gene
- Antibody
Antibody, Epitope, Molecular biology, Monoclonal antibody and Type 1 diabetes are his primary areas of study.
The Antibody study combines topics in areas such as Cell killing, Antigen and Virology.
His biological study spans a wide range of topics, including Jurkat cells and Interleukin 21, CD8, Streptamer.
The various areas that he examines in his Epitope study include Bispecific antibody, Stereochemistry and Immune system.
The concepts of his Molecular biology study are interwoven with issues in Trastuzumab, Monoclonal, Cancer cell, Antibody-dependent cell-mediated cytotoxicity and Wild type.
His work deals with themes such as Progenitor cell, Cancer stem cell, Cancer and CD16, which intersect with Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
